Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety (E01ATCAL0308)

NCT00944268 Phase 3 UNKNOWN

To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety. Clinical study phase III, multicenter, prospective, open. Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.

Details

Lead sponsor	Ativus Farmaceutica Ltda
Phase	Phase 3
Status	UNKNOWN
Enrolment	124
Start date	2009-09
Completion	2010-01

Conditions

• Anxiety
• Efficacy
• Tolerability

Interventions

• Passiflora, Crataegus e Salix

Primary outcomes

• Hamilton Scales — 30 days

Countries

Brazil